<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Insys Therapeutics, Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:87391d00-70ab-418a-987e-b09b7822934f;id=5086</id> <rights type="text">Copyright 2019, Insys Therapeutics, Inc.</rights> <updated>2019-07-03T10:00:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/lK1Y-TfftPKxubnKwwDePg==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/lK1Y-TfftPKxubnKwwDePg==" /> <entry> <id>https://www.globenewswire.com/news-release/2019/07/03/1877750/0/en/FDA-Accepts-New-Drug-Application-for-INSYS-Therapeutics-Naloxone-Nasal-Spray-for-the-Emergency-Treatment-of-Known-or-Suspected-Opioid-Overdose.html</id> <title type="text">FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose</title> <published>2019-07-03T10:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/07/03/1877750/0/en/FDA-Accepts-New-Drug-Application-for-INSYS-Therapeutics-Naloxone-Nasal-Spray-for-the-Emergency-Treatment-of-Known-or-Suspected-Opioid-Overdose.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PHOENIX, July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing. INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose.<br></p>]]></content> <dc:identifier>1877750</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Wed, 03 Jul 2019 10:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/06/12/1867514/0/en/INSYS-Therapeutics-Inc-Receives-Court-Approval-of-First-Day-Motions.html</id> <title type="text">INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions</title> <published>2019-06-12T12:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/06/12/1867514/0/en/INSYS-Therapeutics-Inc-Receives-Court-Approval-of-First-Day-Motions.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Operations to Continue in the Ordinary Course During Court-Supervised Process <pre>Operations to Continue in the Ordinary Course During Court-Supervised Process</pre>]]></content> <dc:identifier>1867514</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Wed, 12 Jun 2019 12:01 GMT</dc:modified> <dc:subject>Bankruptcy</dc:subject> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/06/10/1866165/0/en/INSYS-Therapeutics-Initiates-Court-Supervised-Process-to-Facilitate-Asset-Sales-and-Address-Legacy-Liabilities.html</id> <title type="text">INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities</title> <published>2019-06-10T10:07:26Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/06/10/1866165/0/en/INSYS-Therapeutics-Initiates-Court-Supervised-Process-to-Facilitate-Asset-Sales-and-Address-Legacy-Liabilities.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><em>Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code</em><br></p>]]></content> <dc:identifier>1866165</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 10 Jun 2019 10:07 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/05/10/1822144/0/en/INSYS-Therapeutics-Reports-First-Quarter-2019-Results.html</id> <title type="text">INSYS Therapeutics Reports First Quarter 2019 Results</title> <published>2019-05-10T23:05:09Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/05/10/1822144/0/en/INSYS-Therapeutics-Reports-First-Quarter-2019-Results.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center"><strong><em>Company Continues to Execute Against Pipeline-Focused Strategy</em></strong><br><strong><em>New Drug Application Submitted for Proprietary Naloxone Nasal Spray Formulation</em></strong><br><strong><em>Company Provides Liquidity Update</em></strong></p>]]></content> <dc:identifier>1822144</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Fri, 10 May 2019 23:05 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/04/15/1803975/0/en/INSYS-Therapeutics-Implements-Leadership-Changes.html</id> <title type="text">INSYS Therapeutics Implements Leadership Changes</title> <published>2019-04-15T12:30:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/04/15/1803975/0/en/INSYS-Therapeutics-Implements-Leadership-Changes.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Andrew G. Long Appointed Chief Executive Officer <pre>Andrew G. Long Appointed Chief Executive Officer</pre>]]></content> <dc:identifier>1803975</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 15 Apr 2019 12:30 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/03/25/1759945/0/en/INSYS-Therapeutics-to-Present-Poster-of-Pharmacokinetic-Study-of-Naloxone-Novel-Nasal-Spray-at-The-College-on-Problems-of-Drug-Dependence-Annual-Scientific-Meeting.html</id> <title type="text">INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting</title> <published>2019-03-25T10:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/03/25/1759945/0/en/INSYS-Therapeutics-to-Present-Poster-of-Pharmacokinetic-Study-of-Naloxone-Novel-Nasal-Spray-at-The-College-on-Problems-of-Drug-Dependence-Annual-Scientific-Meeting.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PHOENIX, March 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time.<br></p>]]></content> <dc:identifier>1759945</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 25 Mar 2019 10:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/03/07/1750160/0/en/INSYS-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2018-Results.html</id> <title type="text">INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results</title> <published>2019-03-07T21:15:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/03/07/1750160/0/en/INSYS-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2018-Results.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Strategic Transformation Building Momentum with Two Planned NDAs in 2019 <pre>Strategic Transformation Building Momentum with Two Planned NDAs in 2019</pre>]]></content> <dc:identifier>1750160</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Thu, 07 Mar 2019 21:15 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/03/06/1749186/0/en/INSYS-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2018-Results-on-March-7.html</id> <title type="text">INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7</title> <published>2019-03-06T21:15:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/03/06/1749186/0/en/INSYS-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2018-Results-on-March-7.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>PHOENIX, March 06, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, Mar. 7, after the U.S. financial markets close.<br></p>]]></content> <dc:identifier>1749186</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Wed, 06 Mar 2019 21:15 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/02/25/1741354/0/en/INSYS-Therapeutics-Presented-Poster-of-Initial-Pharmacokinetic-Study-of-Epinephrine-Nasal-Spray-for-the-Emergency-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis-at-Am.html</id> <title type="text">INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting</title> <published>2019-02-25T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/02/25/1741354/0/en/INSYS-Therapeutics-Presented-Poster-of-Initial-Pharmacokinetic-Study-of-Epinephrine-Nasal-Spray-for-the-Emergency-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis-at-Am.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PHOENIX, Feb. 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, presented a poster of its initial pharmacokinetic (PK) study of comparative bioavailability of epinephrine nasal spray and EpiPen<sup>®</sup> in adults with seasonal allergies at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, California on Feb. 24, 2019.<br></p>]]></content> <dc:identifier>1741354</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 25 Feb 2019 11:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/01/09/1682625/0/en/INSYS-Therapeutics-Announces-Results-of-Dose-Finding-PK-Study-for-Epinephrine-Nasal-Spray-for-Treatment-of-Anaphylaxis.html</id> <title type="text">INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis</title> <published>2019-01-09T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/01/09/1682625/0/en/INSYS-Therapeutics-Announces-Results-of-Dose-Finding-PK-Study-for-Epinephrine-Nasal-Spray-for-Treatment-of-Anaphylaxis.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection <pre>Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection</pre>]]></content> <dc:identifier>1682625</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Wed, 09 Jan 2019 11:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2019/01/03/1679962/0/en/INSYS-Therapeutics-to-Present-at-37th-Annual-J-P-Morgan-Healthcare-Conference.html</id> <title type="text">INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference </title> <published>2019-01-03T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2019/01/03/1679962/0/en/INSYS-Therapeutics-to-Present-at-37th-Annual-J-P-Morgan-Healthcare-Conference.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>PHOENIX, Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the J.P. Morgan Healthcare Conference as follows:<br></p>]]></content> <dc:identifier>1679962</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Thu, 03 Jan 2019 11:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/12/18/1668539/0/en/INSYS-Therapeutics-Announces-Participation-at-FDA-Advisory-Committee-Meeting-Addressing-the-Co-Prescribing-of-Naloxone.html</id> <title type="text">INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone</title> <published>2018-12-18T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/12/18/1668539/0/en/INSYS-Therapeutics-Announces-Participation-at-FDA-Advisory-Committee-Meeting-Addressing-the-Co-Prescribing-of-Naloxone.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PHOENIX, Dec. 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018.<br></p>]]></content> <dc:identifier>1668539</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Tue, 18 Dec 2018 11:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/12/17/1667742/0/en/INSYS-Therapeutics-Provides-Update-on-Strategic-Alterative-Review-Process-and-Product-Pipeline-Spanning-Pharmaceutical-Cannabinoids-and-Spray-Technology.html</id> <title type="text">INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology</title> <published>2018-12-17T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/12/17/1667742/0/en/INSYS-Therapeutics-Provides-Update-on-Strategic-Alterative-Review-Process-and-Product-Pipeline-Spanning-Pharmaceutical-Cannabinoids-and-Spray-Technology.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Transformational momentum building as Company plans to apply for two NDAs in 2019 <pre>Transformational momentum building as Company plans to apply for two NDAs in 2019</pre>]]></content> <dc:identifier>1667742</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 17 Dec 2018 11:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/12/04/1661469/0/en/INSYS-Therapeutics-Presents-New-Clinical-Data-from-Long-Term-Safety-Study-of-CBD-Oral-Solution-in-Refractory-Pediatric-Epilepsy.html</id> <title type="text">INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy</title> <published>2018-12-04T11:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/12/04/1661469/0/en/INSYS-Therapeutics-Presents-New-Clinical-Data-from-Long-Term-Safety-Study-of-CBD-Oral-Solution-in-Refractory-Pediatric-Epilepsy.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical data from a long-term safety study presented yesterday at the American Epilepsy Society (AES) 2018 annual meeting.<br></p>]]></content> <dc:identifier>1661469</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Tue, 04 Dec 2018 11:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/11/20/1654358/0/en/Clinical-Data-from-Long-Term-Safety-Study-of-Company-s-Pharmaceutical-CBD-in-Refractory-Pediatric-Epilepsy-To-Be-Presented-at-American-Epilepsy-Society-Meeting.html</id> <title type="text">Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting</title> <published>2018-11-20T12:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/11/20/1654358/0/en/Clinical-Data-from-Long-Term-Safety-Study-of-Company-s-Pharmaceutical-CBD-in-Refractory-Pediatric-Epilepsy-To-Be-Presented-at-American-Epilepsy-Society-Meeting.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PHOENIX, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory pediatric epilepsy will be presented on Dec. 3 at the 2018 American Epilepsy Society (AES) annual meeting in New Orleans. The product candidate evaluated in the study is from INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology.<br></p>]]></content> <dc:identifier>1654358</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Tue, 20 Nov 2018 12:01 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:keyword>pharmaceuticals</dc:keyword> <dc:keyword>healthcare</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/11/05/1645547/0/en/INSYS-Therapeutics-Reports-Third-Quarter-2018-Results.html</id> <title type="text">INSYS Therapeutics Reports Third Quarter 2018 Results</title> <published>2018-11-05T21:16:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/11/05/1645547/0/en/INSYS-Therapeutics-Reports-Third-Quarter-2018-Results.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left"><strong>Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials</strong><br></p>]]></content> <dc:identifier>1645547</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 05 Nov 2018 21:16 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/11/05/1645540/0/en/INSYS-Therapeutics-to-Assess-Strategic-Alternatives-for-Opioid-Related-Assets.html</id> <title type="text">INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets</title> <published>2018-11-05T21:15:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/11/05/1645540/0/en/INSYS-Therapeutics-to-Assess-Strategic-Alternatives-for-Opioid-Related-Assets.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left"><strong>Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology</strong></p>]]></content> <dc:identifier>1645540</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 05 Nov 2018 21:15 GMT</dc:modified> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html</id> <title type="text">INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose</title> <published>2018-11-01T10:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">PHOENIX, Nov. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), today announced that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray formulations for the treatment of opioid overdose showed a distinctive PK profile compared to the current standards of intramuscular (IM) and intravenous (IV) administration of naloxone.<br></p>]]></content> <dc:identifier>1640890</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Thu, 01 Nov 2018 10:01 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://resource.globenewswire.com/Resource/Download/e3898b15-e29a-4769-ab49-1a42f0748610"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html"> <img src="https://resource.globenewswire.com/Resource/Download/e3898b15-e29a-4769-ab49-1a42f0748610" width="600" align="left" border="0" alt="Mean Unconjugated Naloxone Concentrations On Linear Scale" title="PK Profile" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>pharmaceuticals</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/22/1625059/0/en/INSYS-Therapeutics-to-Report-Third-Quarter-2018-Results-on-Nov-5.html</id> <title type="text">INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5</title> <published>2018-10-22T21:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/22/1625059/0/en/INSYS-Therapeutics-to-Report-Third-Quarter-2018-Results-on-Nov-5.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">PHOENIX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its third quarter 2018 financial results on Monday, Nov. 5, after the U.S. financial markets close.<br></p>]]></content> <dc:identifier>1625059</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Mon, 22 Oct 2018 21:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2018/10/12/1620433/0/en/INSYS-Therapeutics-and-UC-San-Diego-s-Center-for-Medicinal-Cannabis-Research-Add-Anxiety-in-Anorexia-Nervosa-to-Series-of-Collaborative-Cannabidiol-CBD-Studies.html</id> <title type="text">INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies</title> <published>2018-10-12T10:00:00Z</published> <updated>2024-11-25T18:16:58Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/10/12/1620433/0/en/INSYS-Therapeutics-and-UC-San-Diego-s-Center-for-Medicinal-Cannabis-Research-Add-Anxiety-in-Anorexia-Nervosa-to-Series-of-Collaborative-Cannabidiol-CBD-Studies.html" /> <category term="Nasdaq:INSY" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US45824V2097" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution <pre>To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution</pre>]]></content> <dc:identifier>1620433</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor> <dc:modified>Fri, 12 Oct 2018 10:00 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:keyword>healthcare</dc:keyword> <dc:keyword>pharmaceuticals</dc:keyword> </entry> </feed>